---
title: "Biohaven Ltd. (BHVN.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/BHVN.US/overview.md"
symbol: "BHVN.US"
name: "Biohaven Ltd."
parent: "https://longbridge.com/zh-CN/quote/BHVN.US.md"
datetime: "2026-04-05T12:53:54.335Z"
locales:
  - [en](https://longbridge.com/en/quote/BHVN.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BHVN.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BHVN.US/overview.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/BHVN.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/BHVN.US/overview.md)


# Biohaven Ltd. (BHVN.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | Biotechnology |
| 交易所 | US Market |
| 地址 | 215 Church Street, New Haven, Connecticut, United States |
| 官网 | [www.biohaven.com](https://www.biohaven.com) |

## 公司简介

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus.

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Vladimir Coric | Chairman & CEO |
| Matthew Buten | Chief Financial Officer |
| Bruce D. Car | Chief Scientific Officer |
| Kimberly Gentile | Senior Vice President of Clinical Operations |
| Deb Young | Senior Director of Regulatory Affairs & Operations |
| Douglas Gray | Corporate Secretary & Director |
| Michael Thomas Heffernan | Lead Independent Director |
| Gregory H. Bailey | Independent Director |
| John Winston Childs | Independent Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| Janus Henderson Group plc | 11.17% | 2026-01-30 |
| Suvretta Capital Management, LLC | 6.84% | 2025-12-31 |
| Stifel Asset Management Corp. | 6.61% | 2025-12-31 |
| John Winston Childs | 6.57% | 2025-11-13 |
| BlackRock, Inc. | 6.28% | 2025-12-31 |
| Infinitum Asset Management, Llc | 4.16% | 2025-12-31 |
| State Street Global Advisors, Inc. | 3.80% | 2025-12-31 |
| TCG Crossover Management, LLC | 3.08% | 2025-12-31 |
| The Vanguard Group, Inc. | 2.92% | 2025-12-31 |
| Vladimir Coric | 2.56% | 2026-01-05 |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**